New Delhi: Glenmark is the first to launch in India a unique I.V. injection formulation, AKYNZEO ® I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV). It offers prevention from both acute and delayed phases of chemotherapy-induced nausea and vomiting.
AKYNZEO ® I.V. is a fixed-dose combination of fosnetupitant (235mg) and palonosetron (0.25mg), which will be available as a single-dose, ready-to-dilute I.V. injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV.
The drug is already being marketed in the EU, the US, and Australia. In India, it will be sold under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.
As per the latest National Cancer Registry Programme data, cancer cases in the country are projected to rise by 12.8% by 2025 from 13.9 lakh cases in 2020.
“AKYNZEO® I.V would provide a new prophylactic option for patients in India, undergoing chemotherapy and who are at risk of CINV. We are delighted to partner with Glenmark which has an excellent footprint in this region and is trusted with providing the best treatment options for cancer patients,” Helsinn Group CEO, Giorgio Calderari, said.
Glenmark was the first to introduce new and effective prophylactic treatment options for CINV among cancer patients in India. Around two decades ago, it launched Aprecap ® (Aprepitant Capsules), the first NK 1 receptor blocker, and a few years later, introduced Aprecap ® I.V. injection. Subsequently in 2018, Glenmark claimed to have revolutionized cancer supportive care in the country by launching AKYNZEO ® Oral Capsules, the first and only CINV prevention therapy to prevent both acute and delayed phases of CINV by a single dose.
“Chemotherapy is the most common form of cancer treatment, with nausea and vomiting being two of its most debilitating side effects. AKYNZEO ® I.V. is a convenient, single-dose, ready-to-dilute I.V. injection that covers, both, the acute and the
delayed phases of CINV, thereby enabling patients to avoid multiple antiemetic drugs, and improving compliance,” Alok Malik, Executive Vice President and Business Head of India Formulations, Glenmark Pharmaceuticals Ltd., said.
– global bihari bureau
